Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study.

Numerically higher ORRs were observed in patients with treatment-naïve disease versus recurrent metastasis (64.0 vs 55.8%), males versus females (63.0 vs 42.9%), patients with oligometastases versus polymetastases (65.0 vs 56.6%), and in patients who received local treatment versus those who did not (67.7 vs 55.0%), but these differences did not reach statistical significance.

also in 111,027 other papers